BIOREGENX, INC.
OTC · CIK 0001593184 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$426,175
Cost Of Revenue
$77,887
Gross Profit
$348,288
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $426,175 | - | - |
| Cost Of Revenue | $77,887 | - | - |
| Gross Profit | $348,288 | - | - |
| Operating Income | $-49,764 | - | - |
| Net Income | $-26,415 | - | - |
| Eps Basic | 0 | - | - |
| Eps Diluted | 0 | - | - |
| Total Assets | $337,070 | - | - |
| Total Liabilities | $4.9M | - | - |
| Shareholders Equity | $-4.5M | - | - |
| Operating Cash Flow | $26,629 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | BIOREGENX, INC. | 2026-05-20 | 0001683168-26-004178 |
| 10-K | BIOREGENX, INC. | 2026-04-15 | 0001683168-26-002975 |
| 10-Q | BIOREGENX, INC. | 2025-11-14 | 0001683168-25-008429 |
| 10-Q | BIOREGENX, INC. | 2025-08-14 | 0001683168-25-006157 |